DOI: 10.1097/dcr.0000000000003152 ISSN: 0012-3706

Aggressive Angiomyxoma of the Pelvis: 35-year Experience

Francisco J. Cardenas Lara, Justin Bauzon, William R.G. Perry, Scott R Kelley
  • Gastroenterology
  • General Medicine


Aggressive angiomyxoma is a very rare mesenchymal tumor most commonly found in the pelvic and perineal regions. Although many are estrogen and progesterone hormone receptor positive, the pathogenesis is unknown. Due to the rarity, there is a paucity of literature relating to this pathology. This paper presents a case-series on the management of aggressive angiomyxoma of the pelvis.


To present a 35-year experience managing aggressive angiomyxoma of the pelvis.


This was a retrospective single system analysis.


This study was conducted at a quaternary referral academic healthcare system.


All patients treated for aggressive angiomyxoma of the pelvis.


All patients underwent surgical and/or medical management of their disease.


The primary outcomes were disease recurrence and mortality. Secondary outcomes included risk factors for recurrence.


A total of 32 patients (94% female) were identified with a median follow-up of 65 months. Thirty (94%) underwent operative resection and 2 were treated solely with medical management. Fifteen achieved an R0 resection (negative microscopic margins) at the index operation, of which 4 (27%) experienced tumor recurrence. There were no mortalities. No risk factors for disease recurrence were identified.


Limitations to our study include its nonrandomized retrospective nature, single healthcare system experience, and small patient sample size.


Aggressive angiomyxoma is a rare, slow-growing tumor with locally invasive features and high potential for recurrence even after resection with negative margins. Imaging modalities such as CT and/or MRI should be obtained to aid in diagnosis and surgical planning. Workup should be paired with preoperative biopsy and testing for hormone receptor status, which can increase diagnostic accuracy and guide medical treatment. Close post-treatment surveillance is imperative to detect recurrence. See Video Abstract.

More from our Archive